Analyze the ethical culture at TAP. Does the culture appear to be in alignment? Misalignment?

Ethics in the Workplace Case Study Action Plan- TAP Pharmacy

Determine all the facts: symptoms of problems and root problems in the case attached.

AN UNETHICAL CULTURE IN NEED OF CHANGE: TAP PHARMACEUTICALS

In 1995, Douglas Durand was offered the position of vice-president for sales at TAP Pharmaceuticals. TAP had been formed 25 years before by Takeda Chemical Industries of Japan and Abbott Laboratories. Doug, 50 years old at the time, had married his high school sweetheart and worked for Merck & Co. for 20 years, working his way up in the sales organization to senior regional director. TAP offered him the opportunity to earn 40 percent more per year (in addition to a $50,000 signing bonus) and help the company move from niche player to mass market purveyor of ulcer and prostate cancer medicine. He took advantage of the opportunity and looked forward to the challenge.

But only a few months after arriving at TAP, he was shocked to find a very different culture from the one he had become accustomed to at Merck. Merck has long had a reputation for ethics and social responsibility and this had been borne out in
Durand’s two decades of experience. For example, at Merck, every new marketing campaign was evaluated by a legal and regulatory team before being launched, and drugs were pulled back if necessary. But TAP turned out to be very different. It
quickly became clear that this was a culture where only numbers mattered. On his very first day on the job, Durand learned that TAP had no in-house legal counsel.

The legal counsel was considered a “sales prevention department.” At one point, Durand found himself listening in on a conference call where sales representatives were openly discussing bribing urologists with an up-front “administration fee” to doctors who prescribed Lupron, the company’s new drug for prostate cancer. TAP sales representatives also gave doctors Lupron samples at a discount or for free, and then encouraged the doctors to charge Medicare full price and keep the difference. He overheard doctors boasting about their Lupron purchases of boats and second homes. TAP offered a big screen TV to every urologist in the country (10,000!), along with offers of office equipment and golf vacations. And reps weren’t accounting for the free samples they gave away, as required by law. Durand knew that failure to account for a single dose can lead to a fine of as much as $1 million. Finally, rather than selling drugs based upon good science, TAP held parties for doctors. One such party for a new ulcer drug featured “Tummy,” a giant fire-belching stomach. Durand soon became frantic and worried about his own guilt by association. Initially, he tried to change the culture. After all, he had been hired as a vice president. But, everything he tried was resisted. He was told that he just didn’t understand the culture at TAP. When he talked about the importance of earning physicians’ trust, the sales reps just rolled their eyes. He then tried to influence change “the TAP way” by offering a bonus to reps who kept accurate records of their samples. The program actually worked, but then senior management discontinued the bonus, and, of course, the reps stopped keeping track. Over time, he found himself excluded from meetings and he felt trapped. What would happen to him if he left this new job in less than a year? He wouldn’t collect his bonus and he wondered if anyone else would hire him. What would happen to his family? But he also worried about becoming the corporate scapegoat.

In desperation, Durand turned to an old friend he knew from Merck, Glenna Crooks, now president of Strategic Health Policy International. Appalled by what she heard, Crooks encouraged him to document the abuses he had observed and
share the information with Elizabeth Ainslie, a Philadelphia attorney. Given the documented fraud against the U.S. government, Ainslie encouraged Durand to sue TAP under the federal whistle-blower program. Armed with documents, he filed the suit and federal prosecutors ran with it. Durand left TAP for Astra Merck in 1996. But under the whistle-blower program, investigations are conducted in secret. Neither TAP nor Astra Merck was supposed to know about it. The investigation took years and, when called to testify, Durand had to make excuses to take time off from his
new job.

He was uncomfortably living as a “double agent.” In the end, TAP pleaded guilty to conspiracy to cheat the federal government and agreed to pay a record $875 million fine. In October 2001, Durand collected $77 million ($28 million went to
taxes), his 14 percent share of the fine paid under the federal whistle-blower statute. He retired to Florida to be closer to his parents, but was still looking forward to the unpleasant task of having to testify against six TAP executives, some of whom had worked for him.

Case Questions

1. Analyze the ethical culture at TAP. Does the culture appear to be in alignment? Misalignment?

2. Based on the facts in the case, and what you have learned in Chapter 9, evaluate the culture change effort that Douglas Durand undertook. What cultural systems did he target in the culture change effort? What systems were missing, if any?

3. Why did his culture change effort fail? What would it take for it to succeed?

Obesity has a heritability of 0.75, compared to 0.55 heritability for body weight in general. This difference most likely means that

Please see attached. Work can not be plagarized, as the assignment will be turned into a site to check for plagarized work.

Document Preview:

1. The fact that body weight has a heritability of 0.55 means that

a. 55 percent of the variation in weight among individuals can be attributed to environmental factors.
b. 55 percent of the variation in weight among individuals can be attributed to genetics.
c. 45 percent of the variation in weight among individuals can be attributed to environmental factors.
d. 45 percent of the variation in weight among individuals can be attributed to genetics.

2. Obesity has a heritability of 0.75, compared to 0.55 heritability for body weight in general. This difference most likely means that

a. genes may play a greater role in people who gain weight easily than in the general population.
b. genes play a lesser role in people who gain weight easily than in the general population.
c. environmental factors play a greater role in predisposing a person to become obese than do genetic factors.
d. about 75 different genes have variants associated with obesity.

3. According to body mass index,

a. Kizzy is overweight, Tawanda is obese, and Suzanne is a healthy weight.
b. Kizzy and Tawanda are obese and Suzanne is a healthy weight.
c. Kizzy is obese, Tawanda is overweight, and Suzanne is underweight.
d. Kizzy is of normal weight, Tawanda is overweight, and Suzanne is obese.

4. The cousins’ initial view that body weight is controlled by variants of a single gene or the environment alone is incorrect because

a. genome-wide association studies have implicated at least 50 genome regions in containing genes that affect body weight.
b. many genes are known to affect weight.
c. it is obvious that diet and exercise affect body weight.
d. the heritability is not even close to 1.0
e. all the above

5. Kizzy has to go through several months of medical tests before weight loss surgery is approved. A young physician, proud of being up to date on genetics in medicine, considers the darkness of Kizzy’s skin, which is similar to that of her mother, Yvonee, and…

Attachments:

In two to three pages write the experimental section of the lab report for The Synthesis of Sulfanilamide

In two to three pages write the experimental section of the lab report for The Synthesis of Sulfanilamide. I will attach a lab report example, look at theexperimental section that starts at page 7, and use that as an example of how it should be written. I will also attache the general procedure for this lab in which you will use in writing this section.
thank you and let me know if you have any quotations.

Document Preview:

Experiment #1: Sulfa Antibiotics -Synthesis of Sulfanilamide INTRODUCTION Many people think of the term chemotherapy as relating to specific modern drug treatments used to fight cancer. Actually, modern chemotherapy began in the early 1900’s with the work of Paul Ehrlich, a German medical doctor and researcher, who is known as the father of immunology and chemotherapy. Ehrlich hypothesized that certain dyes could selectively “stain” harmful bacteria cells without harming host cells. He referred to such compounds as “magic bullets” and coined the term chemotherapy as a general descriptor for chemical remedies targeted to selectively kill infectious cells. This definition includes all antibiotics as well as the more recently developed chemotherapeutic agents targeted to selectively kill cancer cells. Ehrlich’s pioneering work on antibiotics, led, among other remedies, to the discovery of salvarsan, an organoarsenic compound found to be highly effective for treatment of syphilis (replacing mercury which had often disastrous side effects). He was awarded the Nobel Prize for medicine in 1908. Building on Ehrlich’s early work, Gerhard Domagk, a medical doctor employed by a German dye manufacturer made a breakthrough discovery by finding that a dye known as prontosil, dosed orally, was effective in curing life threatening streptococci infections in humans. He made the discovery in a desperate, but successful attempt to save his daughter who was dying of a streptococci infection. Domagk’s discovery led to an extremely productive period of discovery in antibiotics. He was awarded the Nobel Prize for medicine in 1939. In 1936, a year after Domagk’s discovery of the anti-streptococcus activity of the dye prontosil, Ernest Fourneau of the Pasteur Institute in Paris discovered that prontosil breaks down in the human body to produce sulfanilamide which is the active agent that kills streptococcus bacteria. Fourneau’s discovery triggered a flurry of research on structural…

Attachments:

discuss how good the health care

The purpose of my report is to discuss how good the health care is and that is the main question of my report. Health care in our country need a lot of work and development which will reduce the Medical errors. I will discuss the quality of hospitals and it’s as medical staff, buildings, and equipment.

Document Preview:

The purpose of my report is to discuss how good the health care is and that is the main question of my report. Health care in our country need a lot of work and development which will reduce the Medical errors. I will discuss the quality of hospitals and it’s as medical staff, buildings, and equipment. If we want to raise the quality of health care we should work to increase the capacity of medical staff to carry out their duties to the fullest and improve the design of buildings to serve large numbers of patients with a high quality using some strategies that will “hopefully” lead us to find logical solutions for the problems.
INTRODUCTION
Hospital
1.1 Efficiency
1.2 Buildings
1.3 Equipment
1.4 Staff
Investment in health
2.1 Insurance companies
2.2 Privet hospital.
Treatments“ the headline need more description”
3.1 Medicines
3.2 Physical Therapy
3.3 Recovery
4.problems and solutions
4.1 ????
4.2 ???? “I need three or two problems with possible solutions”
4.3 ????
5. RECOMMENDATIONS
CONCLUSION
At least 5 sources and the sources must be up to date (2008-2011)
Citation using APA style, and documentations are needed also by APA style
Paraphrased the sources (NO WORDING FROM THE SOURCES)
I need all the sources and highlight what have been taken from the sources with cross references
The report must be at least 1600 words WITHOUT the introduction and conclusion
You can change the outline BUT not very much
You can see my instructor comment for my progress report

Attachments: